ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Acadia Pharma (ACAD) Tops Q2 EPS by 7c; Raises FY Rev Guidance
July 31, 2019 4:09 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.38), $0.07 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $93.2 million versus the consensus estimate of $72.12 million.
Continued execution of our commercial initiatives led to strong quarterly performance for NUPLAZID and a... More
